MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies
MaxCyte’s CEO to Present Update on Life Sciences Business & First-in-class CARMA™ Cellular Therapies at BIO CEO & Investor Conference in New York
MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update
A new biotechnology and pharmaceutical industry commitment to patients and the public.
January 8, 2020
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018.
February 25, 2019
MaxCyte has committed itself to fostering workplace development, diversity, and inclusion (WDDI) at MaxCyte and across the biotechnology industry. We are dedicated to being at the forefront of efforts to develop a diverse and talented global workforce. To that end, we affirmatively support the following WDDI Principles adopted by the Biotechnology Innovation Organization (BIO), and pledge to do our part to foster diversity and inclusion among our employees, customers, and patients.
February 6, 2018
See BIO’s latest periodic updates on key issues facing the advancement of science and the ability of researchers and entrepreneurs to deliver the latest medical and biological breakthroughs to people who need them around the world.
July 26, 2017
Learn about the impact of biotechnology on patients and society, as well as the factors needed to keep the innovation engine running strong.
April 7, 2017
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter